- Home
- ZG vs RPRX Comparison
ZG vs RPRX Comparison
Compare ZG & RPRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ZG
- RPRX
- Stock Information
- Founded
- ZG 2004
- RPRX 1996
- Country
- ZG United States
- RPRX United States
- Employees
- ZG N/A
- RPRX N/A
- Industry
- ZG Business Services
- RPRX Biotechnology: Pharmaceutical Preparations
- Sector
- ZG Consumer Discretionary
- RPRX Health Care
- Exchange
- ZG Nasdaq
- RPRX Nasdaq
- Market Cap
- ZG 17.6B
- RPRX 14.2B
- IPO Year
- ZG 2011
- RPRX 2020
- Fundamental
- Price
- ZG $66.84
- RPRX $30.87
- Analyst Decision
- ZG Buy
- RPRX Strong Buy
- Analyst Count
- ZG 25
- RPRX 5
- Target Price
- ZG $81.71
- RPRX $41.60
- AVG Volume (30 Days)
- ZG 653.0K
- RPRX 4.3M
- Earning Date
- ZG 04-30-2025
- RPRX 05-08-2025
- Dividend Yield
- ZG N/A
- RPRX 2.81%
- EPS Growth
- ZG N/A
- RPRX N/A
- EPS
- ZG N/A
- RPRX 1.91
- Revenue
- ZG $2,236,000,000.00
- RPRX $2,263,576,000.00
- Revenue This Year
- ZG $16.41
- RPRX $33.46
- Revenue Next Year
- ZG $14.79
- RPRX $4.44
- P/E Ratio
- ZG N/A
- RPRX $16.41
- Revenue Growth
- ZG 14.96
- RPRX N/A
- 52 Week Low
- ZG $38.06
- RPRX $24.05
- 52 Week High
- ZG $86.58
- RPRX $34.20
- Technical
- Relative Strength Index (RSI)
- ZG 38.90
- RPRX 31.82
- Support Level
- ZG $67.94
- RPRX $32.26
- Resistance Level
- ZG $72.93
- RPRX $34.14
- Average True Range (ATR)
- ZG 2.34
- RPRX 0.76
- MACD
- ZG -0.02
- RPRX -0.35
- Stochastic Oscillator
- ZG 26.45
- RPRX 6.57
About ZG Zillow Group Inc.
Zillow Group Inc is an Internet-based real estate company that offers its customers an on-demand experience for selling, buying, renting, or financing with transparency and ease The group works with real estate agents, brokers, builders, property managers, and landlords to pair technology with top-notch service. The group has brands such as Zillow, Trulia, StreetEasy, Hotpads, Zillow Rentals, Zillow Premier Agent and others.
About RPRX Royalty Pharma plc
Royalty Pharma PLC is the largest buyer of biopharmaceutical royalties. The firm has a portfolio of royalties that entitles it to payments based on the sales of biopharma products. Royalty Pharma receives royalties on more than 35 commercial products, including AbbVie and Johnson & Johnson's Imbruvica (for chronic lymphocytic leukemia and other blood cancers), Biogen's Tysabri (for relapsing forms of multiple sclerosis), Vertex's cystic fibrosis franchise, and 10 development-stage product candidates.